<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7760260\results\search\disease\results.xml">
  <result pre="series of 3-aminomethylbenzoxaborole derivatives 4 and 5 that target Mycobacterium" exact="tuberculosis" post="(Mtb) LeuRS [20]. The boron atom in the molecules"/>
  <result pre="once daily dose of 50 mg/kg in a mouse acute" exact="tuberculosis" post="(TB) infection model caused serious concerns for its use"/>
  <result pre="is currently in a phase 2 clinical trial for drug-sensitive" exact="pulmonary tuberculosis" post="to evaluate its early bacterial activity, safety, and tolerability"/>
  <result pre="currently in a phase 2 clinical trial for drug-sensitive pulmonary" exact="tuberculosis" post="to evaluate its early bacterial activity, safety, and tolerability"/>
  <result pre="Cryptosporidium parvum both in vitro and in vivo. Compounds for" exact="cryptosporidiosis" post="treatment must also have good exposure in the gastrointestinal"/>
  <result pre="In this regard, compound 21 was worthy of consideration for" exact="cryptosporidiosis" post="since 17% of the oral dose was found in"/>
  <result pre="in the plasma membrane and enhances cell migration that causes" exact="cancer" post="metastasis. Thus, it is thought that directly inhibiting the"/>
  <result pre="between LysRS and 67LR by a small molecule could suppress" exact="cancer" post="metastasis and derive a new class of antimetastatic cancer"/>
  <result pre="suppress cancer metastasis and derive a new class of antimetastatic" exact="cancer" post="therapy. In this regard, 25 showed specific inhibition of"/>
  <result pre="decreased the amount of membranous 67LR using LysRS-overexpressing H226 squamous" exact="lung carcinoma" post="cells (Figure 9). The in vivo efficacy of 25"/>
  <result pre="three different in vivo mouse models, including (i) a mouse" exact="breast cancer" post="model (4T1 cells, 100 mpk [mg per kilogram] and"/>
  <result pre="different in vivo mouse models, including (i) a mouse breast" exact="cancer" post="model (4T1 cells, 100 mpk [mg per kilogram] and"/>
  <result pre="po, ~70% reduction of pulmonary nodule formation), and (iii) a" exact="cancer" post="cell colonization model (A549 cells expressing red fluorescence protein"/>
  <result pre="mutations in the ProRS domain of GluProRS lead to hypomyelinating" exact="leukodystrophy" post="without causing any known cardiac dysfunction in patients, implying"/>
  <result pre="In this regard, Akashi Therapeutics used 26 to treat Duchenne" exact="muscular dystrophy" post="(DMD), analogous to reducing fibrosis by 26 and increasing"/>
  <result pre="variant of AIMP2 lacking exon 2 (AIMP2-DX2) correlates positively with" exact="cancer" post="by compromising the tumor-suppressive function of native AIMP2 through"/>
  <result pre="absentia homolog 1 (Siah1)-dependent ubiquitination of AIMP2-DX2, which leads to" exact="cancer" post="progression in vivo [44]. Representative AIMP2-DX2 inhibitors (28~30) are"/>
  <result pre="to specifically inhibit the AIMP2-DX2 + HSP70 interaction and suppress" exact="cancer" post="cell growth in vitro (IC50 = 4.2 Î¼M, luciferase"/>
  <result pre="a multi-drug resistant strain, Pf Dd2) for the treatment of" exact="malaria" post="[47]. Lead optimization campaign allowed the improvement of in"/>
  <result pre="In vivo efficacy studies of 32 in multiple stages of" exact="malaria" post="models including Plasmodium berghei CD-1 and P. falciparum huRBC"/>
  <result pre="has served as an example of developing a cure for" exact="malaria" post="as well as the potential to give prophylaxis and"/>
  <result pre="young children [48]. The in vivo efficacy of 32 for" exact="cryptosporidiosis" post="was shown in immunosuppressed mouse models. Overall, it is"/>
  <result pre="(GlySAs, Figure 13) as human glycyl-tRNA synthetase (GlyRS) inhibitors for" exact="cancer" post="therapy by lowering neddylation [49]. The covalent attachment of"/>
  <result pre="GlyRS is highly expressed in most malignant cancers, such as" exact="breast cancer," post="ovarian cancer, and lung cancer. Selective binding of GlySAs"/>
  <result pre="highly expressed in most malignant cancers, such as breast cancer," exact="ovarian cancer," post="and lung cancer. Selective binding of GlySAs to the"/>
  <result pre="most malignant cancers, such as breast cancer, ovarian cancer, and" exact="lung cancer." post="Selective binding of GlySAs to the catalytic domain of"/>
  <result pre="the level of neddylation by more than 50% in various" exact="cancer" post="cells. The patent provided the systematic mode of action"/>
  <result pre="of growth inhibition values (GI50 = 0.372â€&quot;3.715 Î¼M) in 58" exact="cancer" post="cell lines. With the lung metastasis model induced by"/>
  <result pre="brucei methionyl-tRNA synthetase (MetRS) inhibitors for the treatment of African" exact="trypanosomiasis" post="and sleeping sickness [56,57]. Two major classes of compounds"/>
  <result pre="synthetase (MetRS) inhibitors for the treatment of African trypanosomiasis and" exact="sleeping sickness" post="[56,57]. Two major classes of compounds incorporating tetracyclic tetrahydro-beta-carboline"/>
  <result pre="inhibitors of secondary amines for killing Gram-negative bacteria and treating" exact="tuberculosis" post="[58]. Although the target enzyme is not specifically mentioned"/>
  <result pre="the Gram-negative (E.coli and Acinetobacter baumannii (A.bau)) MIC protocol and" exact="tuberculosis" post="luminescence assay. Among these compounds, the methyl substitution of"/>
  <result pre="33 Î¼M (A.bau) against Gram-negative bacteria as well as Mycobacterium" exact="tuberculosis" post="(MTB) activity of 10 Î¼M against H37Rv WT. Furthermore,"/>
  <result pre="The cell viability assay of the aa-SAs was performed in" exact="prostate cancer" post="cell lines, and IC50 values of 0.0015â€&quot;27 Î¼M for"/>
  <result pre="cell viability assay of the aa-SAs was performed in prostate" exact="cancer" post="cell lines, and IC50 values of 0.0015â€&quot;27 Î¼M for"/>
  <result pre="PC3 were observed. For L-Gln-lactam-SA (89), a panel of other" exact="cancer" post="cell lines was tested for cell viability to give"/>
  <result pre="the aforementioned patent (WO 2018147626 A1), for the treatment of" exact="idiopathic pulmonary fibrosis" post="(IPF). In IPF patient-derived primary lung fibroblasts, treatment with"/>
  <result pre="aforementioned patent (WO 2018147626 A1), for the treatment of idiopathic" exact="pulmonary fibrosis" post="(IPF). In IPF patient-derived primary lung fibroblasts, treatment with"/>
  <result pre="growth factor-Î² (TGF-Î²) induction. In the mouse model of bleomycin-induced" exact="pulmonary fibrosis," post="oral administration of 91 for 2 weeks significantly reduced"/>
  <result pre="GSK070) as a pLeuRS inhibitor for the treatment of M." exact="tuberculosis" post="infection (MTBI), in-licensed from Anacor Pharmaceuticals. Notably, 8 inhibited"/>
  <result pre="e-275 (Sanofi-Aventis) in patients (expected n = 80) with drug-sensitive" exact="pulmonary tuberculosis" post="in South Africa [74]. This study was designed to"/>
  <result pre="(Sanofi-Aventis) in patients (expected n = 80) with drug-sensitive pulmonary" exact="tuberculosis" post="in South Africa [74]. This study was designed to"/>
  <result pre="syndrome (ASSD) is a heterogeneous group of autoimmune diseases, including" exact="interstitial lung disease" post="(ILD), myositis, mechanicâ€™s hands, Raynaudâ€™s phenomenon, and arthritis. ASSD"/>
  <result pre="(ASSD) is a heterogeneous group of autoimmune diseases, including interstitial" exact="lung disease" post="(ILD), myositis, mechanicâ€™s hands, Raynaudâ€™s phenomenon, and arthritis. ASSD"/>
  <result pre="[77,78]. ARSs are also dysregulated in other autoimmune diseases, including" exact="multiple sclerosis," post="rheumatoid arthritis, immune thrombocytopenia, and systemic lupus erythematosus [79,80,81,82]."/>
  <result pre="are also dysregulated in other autoimmune diseases, including multiple sclerosis," exact="rheumatoid arthritis," post="immune thrombocytopenia, and systemic lupus erythematosus [79,80,81,82]. For example,"/>
  <result pre="autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, immune thrombocytopenia, and" exact="systemic lupus erythematosus" post="[79,80,81,82]. For example, Wang et al. analyzed the interaction"/>
  <result pre="diseases, including multiple sclerosis, rheumatoid arthritis, immune thrombocytopenia, and systemic" exact="lupus erythematosus" post="[79,80,81,82]. For example, Wang et al. analyzed the interaction"/>
  <result pre="the direct correlation of ThrRS levels with disease stage in" exact="ovarian cancer" post="patients is derived from ThrRS-regulated angiogenesis and immune cell"/>
  <result pre="direct correlation of ThrRS levels with disease stage in ovarian" exact="cancer" post="patients is derived from ThrRS-regulated angiogenesis and immune cell"/>
  <result pre="immune cell responses [85]. Additionally, Adam et al. discovered that" exact="cancer" post="cells could upregulate TrpRS in two different ways to"/>
  <result pre="cells jointly induce the expression of IDO1 and TrpRS in" exact="breast cancer," post="colon carcinoma, and B-cell lymphoma by secreting IFN-Î³ [86]."/>
  <result pre="IDO1 and TrpRS in breast cancer, colon carcinoma, and B-cell" exact="lymphoma" post="by secreting IFN-Î³ [86]. As far as we understand,"/>
  <result pre="reasonable to expect that more clinical studies will emerge for" exact="cancer" post="therapeutics in the near future. The role of ARS"/>
  <result pre="distinct pathways: Threonyl-tRNA synthetase and caspases are independently involved in" exact="suppression" post="of proliferation and induction of apoptosis in endothelial cellsJ."/>
  <result pre="20.PalenciaA.LiX.BuW.ChoiW.DingC.Z.EasomE.E.FengL.HernandezV.HoustonP.LiuL.et al.Discovery of novel oral protein synthesis inhibitors of Mycobacterium" exact="tuberculosis" post="that target leucyl-tRNA synthetaseAntimicrob. Agents Chemother.2016606271628010.1128/AAC.01339-1627503647 21.XianfengL.VincentH.FernandoL.R.WaiC.YvonneS.L.MakM.M.WeiminM.YasheenZ.EricE.E.JacobJ.et al.Discovery of"/>
  <result pre="Agents Chemother.2016606271628010.1128/AAC.01339-1627503647 21.XianfengL.VincentH.FernandoL.R.WaiC.YvonneS.L.MakM.M.WeiminM.YasheenZ.EricE.E.JacobJ.et al.Discovery of a Potent and Specific M." exact="tuberculosis" post="Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)J. Med. Chem.2017608011802628953378 22.DavidT.GeoD.AlexC.JohnT.MattD.SimonC.StephanieG.AlisonG.AdeepP.MorrisM.et al.First-Time-in-Human"/>
  <result pre="Chem. Biol.2020151016102510.1021/acschembio.0c0003232195573 29.BaragaÃ±aB.ForteB.ChoiR.HewittS.N.Bueren-CalabuigJ.A.PiscoJ.P.PeetC.DranowD.M.RobinsonD.A.JansenC.et al.Lysyl-tRNA synthetase as a drug target in" exact="malaria" post="and cryptosporidiosisProc. Natl. Acad. Sci. USA20191167015702010.1073/pnas.181468511630894487 30.NovoaE.M.CamachoN.TorA.WilkinsonB.MossS.MarÃ­n-GarcÃ­aP.AzcÃ¡rateI.G.BautistaJ.M.MirandoA.C.FrancklynC.S.et al.Analogs of"/>
  <result pre="Sci. USA20191167015702010.1073/pnas.181468511630894487 30.NovoaE.M.CamachoN.TorA.WilkinsonB.MossS.MarÃ­n-GarcÃ­aP.AzcÃ¡rateI.G.BautistaJ.M.MirandoA.C.FrancklynC.S.et al.Analogs of natural aminoacyl-tRNA synthetase inhibitors clear" exact="malaria" post="in vivoProc. Natl. Acad. Sci. USA2014111E5508E551710.1073/pnas.140599411125489076 31.KimD.G.LeeJ.Y.KwonN.H.FangP.ZhangQ.WangJ.YoungN.L.GuoM.ChoH.Y.MushtaqA.U.et al.Chemical inhibition"/>
  <result pre="Biol.2012416417310.1093/jmcb/mjs01822532625 44.LimS.ChoH.Y.KimD.G.RohY.SonS.Y.MushtaqA.U.KimM.BhattaraiD.SivaramanA.LeeY.et al.Targeting the interaction of AIMP2-DX2 with HSP70 suppresses" exact="cancer" post="developmentNat. Chem. Biol.202016314110.1038/s41589-019-0415-231792442 45.SivaramanA.KimD.G.BhattaraiD.KimM.LeeH.Y.LimS.KongJ.GooJ.I.ShimS.LeeS.et al.Synthesis and structureâˆ’activity relationships of"/>
  <result pre="inhibitors of aminoacyl-tRNA synthetase interacting multifunctional protein 2 (AIMP2)-DX2 for" exact="lung cancer" post="treatmentJ. Med. Chem.2020633908391410.1021/acs.jmedchem.9b0176532208684 47.KatoN.ComerE.Sakata-KatoT.SharmaA.SharmaM.Maetani1M.BastienJ.BrancucciN.M.BittkerJ.A.CoreyV.et al.Diversity-oriented synthesis yields novel multistage"/>
  <result pre="of aminoacyl-tRNA synthetase interacting multifunctional protein 2 (AIMP2)-DX2 for lung" exact="cancer" post="treatmentJ. Med. Chem.2020633908391410.1021/acs.jmedchem.9b0176532208684 47.KatoN.ComerE.Sakata-KatoT.SharmaA.SharmaM.Maetani1M.BastienJ.BrancucciN.M.BittkerJ.A.CoreyV.et al.Diversity-oriented synthesis yields novel multistage"/>
  <result pre="longitudinal cohort study of the anti-synthetase syndrome: Increased severity of" exact="interstitial lung disease" post="in black patients and patients with anti-PL7 and anti-PL12"/>
  <result pre="cohort study of the anti-synthetase syndrome: Increased severity of interstitial" exact="lung disease" post="in black patients and patients with anti-PL7 and anti-PL12"/>
  <result pre="CD4+ T cellsBlood20051051574158110.1182/blood-2004-06-208915466932 84.WangS.MaoC.ZhaoZ.GuQ.JinM.XiaoY.JiangX.ZhaoY.ZhangY.NingG.Increased TTS abrogates IDO-mediated CD4(+) T cells" exact="suppression" post="in patients with Gravesâ€™ diseaseEndocrine20093611912510.1007/s12020-009-9184-019363598 85.WellmanT.L.EckensteinM.WongC.RinconM.AshikagaT.MountS.L.FrancklynC.S.LounsburyK.M.Threonyl-tRNA synthetase overexpression correlates"/>
  <result pre="human ovarian cancerBMC Cancer20141462010.1186/1471-2407-14-62025163878 86.AdamI.DewiD.L.Upregulation of tryptophanyl-tRNA synthethase adapts human" exact="cancer" post="cells to nutritional stress caused by tryptophan degradationOncoimmunology20187e148635310.1080/2162402X.2018.148635330524887 87.BoczonadiV.JenningM.J.HorvathR.The"/>
  <result pre="of sulfamide adenosine derivatives (aa-SAs) and their biological activities against" exact="prostate cancer" post="cell lines. Figure 21 Chemical structures of DWN12088 and"/>
  <result pre="sulfamide adenosine derivatives (aa-SAs) and their biological activities against prostate" exact="cancer" post="cell lines. Figure 21 Chemical structures of DWN12088 and"/>
  <result pre="2Table 2 Cytotoxicity of L-Gln-lactam-SA (89) against a panel of" exact="cancer" post="cell lines. A Panel of Cancer Cell Lines IC50"/>
  <result pre="Daewoong Pharma eProRS Fibrosis Phase I Not specified (KR) (IPF:" exact="idiopathic pulmonary fibrosis," post="CDI: Clostridium difficile infection, HPI: Helicobacter pylori infection, MTBI:"/>
  <result pre="Pharma eProRS Fibrosis Phase I Not specified (KR) (IPF: idiopathic" exact="pulmonary fibrosis," post="CDI: Clostridium difficile infection, HPI: Helicobacter pylori infection, MTBI:"/>
  <result pre="CDI: Clostridium difficile infection, HPI: Helicobacter pylori infection, MTBI: Mycobacterium" exact="tuberculosis" post="infection, BSI: bacterial skin infection)."/>
 </snippets>
</snippetsTree>
